Literature DB >> 28799163

Cost Analysis and Performance Assessment of Partner Services for Human Immunodeficiency Virus and Sexually Transmitted Diseases, New York State, 2014.

Britney L Johnson1, James Tesoriero2, Wenhui Feng3,4, Feng Qian5, Erika G Martin3,4.   

Abstract

OBJECTIVE: To estimate the programmatic costs of partner services for HIV, syphilis, gonorrhea, and chlamydial infection. STUDY
SETTING: New York State and local health departments conducting partner services activities in 2014. STUDY
DESIGN: A cost analysis estimated, from the state perspective, total program costs and cost per case assignment, patient interview, partner notification, and disease-specific key performance indicator. DATA COLLECTION: Data came from contracts, a time study of staff effort, and statewide surveillance systems. PRINCIPAL
FINDINGS: Disease-specific costs per case assignment (mean: $580; range: $502-$1,111), patient interview ($703; $608-$1,609), partner notification ($1,169; $950-$1,936), and key performance indicator ($2,697; $1,666-$20,255) varied across diseases. Most costs (79 percent) were devoted to gonorrhea and chlamydial infection investigations.
CONCLUSIONS: Cost analysis complements cost-effectiveness analysis in evaluating program performance and guiding improvements. © Health Research and Educational Trust.

Entities:  

Keywords:  zzm321990HIVzzm321990; Partner services; economic evaluation; sexually transmitted diseases

Mesh：

Year:  2017        PMID： 28799163      PMCID： PMC5682127          DOI： 10.1111/1475-6773.12748

Source DB:  PubMed          Journal:  Health Serv Res        ISSN： 0017-9124            Impact factor:   3.402


  26 in total

1.  The Program Science initiative: improving the planning, implementation and evaluation of HIV/STI prevention programs.

Authors:  Sevgi O Aral; James F Blanchard
Journal:  Sex Transm Infect       Date:  2012-02-22       Impact factor: 3.519

2.  Delivering Partner Services to Reduce Transmission and Promote Linkage to Care: Process Outcomes Varied for Chlamydial Infection, Gonorrhea, HIV, and Syphilis Cases.

Authors:  Erika G Martin; Wenhui Feng; Feng Qian; Britney Johnson
Journal:  J Public Health Manag Pract       Date:  2017 May/Jun

3.  Does funding for HIV and sexually transmitted disease prevention matter? Evidence from panel data.

Authors:  Harrell W Chesson; Paul Harrison; Carol R Scotton; Beena Varghese
Journal:  Eval Rev       Date:  2005-02

4.  Public health financial management competencies.

Authors:  Peggy A Honoré; Julia F Costich
Journal:  J Public Health Manag Pract       Date:  2009 Jul-Aug

5.  Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.

Authors:  Sean D Sullivan; Josephine A Mauskopf; Federico Augustovski; J Jaime Caro; Karen M Lee; Mark Minchin; Ewa Orlewska; Pete Penna; Jose-Manuel Rodriguez Barrios; Wen-Yi Shau
Journal:  Value Health       Date:  2013-12-13       Impact factor: 5.725

6.  Developing a predictive model to prioritize human immunodeficiency virus partner notification in North Carolina.

Authors:  Brooke E Hoots; Pia D M MacDonald; Lisa B Hightow-Weidman; Peter A Leone; William C Miller
Journal:  Sex Transm Dis       Date:  2012-01       Impact factor: 2.830

7.  Partner notification for syphilis: a randomized, controlled trial of three approaches.

Authors:  T A Peterman; K E Toomey; L W Dicker; A A Zaidi; J E Wroten; J Carolina
Journal:  Sex Transm Dis       Date:  1997-10       Impact factor: 2.830

8.  Partner notification for HIV and STD in the United States: low coverage for gonorrhea, chlamydial infection, and HIV.

Authors:  Matthew R Golden; Matthew Hogben; H Hunter Handsfield; Janet S St Lawrence; John J Potterat; King K Holmes
Journal:  Sex Transm Dis       Date:  2003-06       Impact factor: 2.830

9.  The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008.

Authors:  Kwame Owusu-Edusei; Harrell W Chesson; Thomas L Gift; Guoyu Tao; Reena Mahajan; Marie Cheryl Bañez Ocfemia; Charlotte K Kent
Journal:  Sex Transm Dis       Date:  2013-03       Impact factor: 2.830

10.  Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group.

Authors:  M L Kamb; M Fishbein; J M Douglas; F Rhodes; J Rogers; G Bolan; J Zenilman; T Hoxworth; C K Malotte; M Iatesta; C Kent; A Lentz; S Graziano; R H Byers; T A Peterman
Journal:  JAMA       Date:  1998-10-07       Impact factor: 56.272
View more
  4 in total

1.  Sexually Transmitted Disease Partner Services Costs, Other Resources, and Strategies Across Jurisdictions to Address Unique Epidemic Characteristics and Increased Incidence.

Authors:  Rachel A Silverman; David A Katz; Carol Levin; Teal R Bell; Dawn Spellman; Lisa St John; Evelyn Manley Rodriguez; Matthew R Golden; Ruanne V Barnabas
Journal:  Sex Transm Dis       Date:  2019-08       Impact factor: 2.830

2.  Outcomes of Traditional and Enhanced Gonorrhea Partner Services in the Strengthening the US Response to Resistant Gonorrhea Project, 2017 to 2019.

Authors:  Emily R Learner; Karen Schlanger; Kerry Mauk; Cau D Pham; Rachel Mukai; Lacy Mulleavey; Roxanne P Kerani; Terilyn Albano; Brandy Sessoms; Justin L Holderman; Brian Toro; Madeline Sankaran; Robert D Kirkcaldy
Journal:  Sex Transm Dis       Date:  2021-12-01       Impact factor: 3.868

3.  Barriers, Facilitators, and Cost of Integrating HIV-Related Activities Into Sexually Transmitted Disease Partner Services in Jackson, Mississippi.

Authors:  Peder Digre; Tigran Avoundjian; Kendra Johnson; David Peyton; Christie Lewis; Ruanne V Barnabas; Matthew R Golden; Christine M Khosropour
Journal:  Sex Transm Dis       Date:  2021-03-01       Impact factor: 2.830

4.  Contact Tracing for COVID-19: An Opportunity to Reduce Health Disparities and End the Human Immunodeficiency Virus/AIDS Epidemic in the United States.

Authors:  Bohdan Nosyk; Wendy S Armstrong; Carlos Del Rio
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.